Leonel Estofan, MD
Epilepsy · Edinburg, TXNPI 1417339409
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,163 of the $8,563 with a category attached, or 83.7%. It is spread thinly across 30 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,380, 7.4 times the $592 reported in 2021.
Across 353 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- UCB, Inc.$1K
- AbbVie$749
- SK Life Science, Inc.$743
- Livanova USA, Inc.$411
- Eisai Inc.$399
- plus $3K from 24 others
Across 8 payments — averaging $12,436 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$99K
What the payments were for
- Travel & lodging$1,31015%
- Food & beverage$7,16384%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 11 | $1,843 |
| UCB, Inc. | 54 | $1,328 |
| AbbVie | 55 | $749 |
| SK Life Science, Inc. | 29 | $743 |
| Livanova USA, Inc. | 13 | $411 |
| Eisai Inc. | 17 | $399 |
| Pfizer | 25 | $347 |
| Jazz Pharmaceuticals Inc. | 12 | $275 |
| Teva Pharmaceuticals USA, Inc. | 17 | $274 |
| Catalyst Pharmaceuticals, Inc. | 12 | $245 |
| Sumitomo Pharma America, Inc. | 29 | $237 |
| Johnson & Johnson | 3 | $228 |
| Lilly USA, LLC | 12 | $218 |
| Lundbeck LLC | 13 | $196 |
| Neurelis, Inc. | 8 | $176 |
| Otter Pharmaceuticals, LLC | 6 | $171 |
| Neurocrine Biosciences, Inc. | 7 | $170 |
| Otsuka America Pharmaceutical, Inc. | 10 | $151 |
| Acadia Pharmaceuticals Inc | 5 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Argenx US, Inc. | 2 | $52 |
| Microtransponder, Inc. | 1 | $40 |
| Amylyx Pharmaceuticals, Inc. | 1 | $28 |
| OWP Pharmaceuticals, Inc. | 1 | $21 |
| Immedica Pharma US, Inc. | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| GE HealthCare | 1 | $16 |
| Aucta Pharmaceuticals, Inc. | 1 | $15 |
| Zogenix Inc. | 1 | $13 |
| Corium, LLC | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VISUALASE$1,298
- XARELTO$213
- XCOPRI$114
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$111
- NEXFRAME$100
How this compares
$8,563 in reported general payments places this provider in the 80th percentile of 36 epilepsy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 31 | $171,579 |
| XcopriCenobamate | 155 | $167,482 |
| BriviactBrivaracetam | 51 | $86,452 |
| Lacosamide | 141 | $36,506 |
| FycompaPerampanel | 29 | $33,842 |
| Rufinamide | 32 | $28,655 |
| Levetiracetam | 398 | $22,282 |
| RexultiBrexpiprazole | 14 | $19,147 |
| Entacapone | 42 | $15,626 |
| NayzilamMidazolam | 17 | $10,489 |
| Everolimus | 12 | $6,204 |
| Clobazam | 58 | $5,000 |
| Ropinirole Hcl | 140 | $3,670 |
| Levetiracetam ErLevetiracetam | 45 | $3,407 |
| Oxcarbazepine | 39 | $3,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $743 | $167,482155 claims |
| UCB, Inc.Briviact, Nayzilam | $1,328 | $96,94168 claims |
| Eisai Inc.Fycompa | $399 | $33,84229 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $151 | $19,14714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 36 epilepsy providers in Texas.
Other epilepsy in Edinburg
- Karen KeoughAustin$474K
- Katherine LabinerAustin$163K
- Jay HarveyDallas$19K
- Charles SzaboSan Antonio$15K
- Daniel GustkeyAustin$12K
- Erin FiedlerDallas$9K
- Linda LearySan Antonio$9K
- Bernhard SuterHouston$6K
- Irfan AliHouston$6K
- James RivielloHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.